Sidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients
Stefano Cascinu(Vita-Salute San Raffaele University), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Davide Poli(Mario Negri Institute for Pharmacological Research), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino)
Cited by 0
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k